# Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma

> **NCT02237261** · PHASE2 · COMPLETED · sponsor: **University Hospital Heidelberg** · enrollment: 46 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bendamustine, Bortezomib, Prednisone

## Key facts

- **NCT ID:** NCT02237261
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02237261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02237261, "Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02237261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*